AB-MECA

Confirm delete?

AB-MECA

Zoom

Cat No: 28415

Biochemicals - Receptor Pharmacology

AB-MECA is an adenosine A3 receptor agonist (Ki = 430.5 nM for the human receptor expressed in CHO cells).{45426} It inhibits LPS-induced TNF-α production in primary cultured human lung macrophages (pD2 = 6.9).{45427} AB-MECA increases contraction of ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

1-[6-[[(4-aminophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-?-D-ribofuranuronamide

Correlated keywords:

A-3 ABMECA TNF? broncho-constriction radio-labeled radio-ligand 1 2a COS7 Chinese Ovary Hamster

Product Overview:
AB-MECA is an adenosine A3 receptor agonist (Ki = 430.5 nM for the human receptor expressed in CHO cells).{45426} It inhibits LPS-induced TNF-α production in primary cultured human lung macrophages (pD2 = 6.9).{45427} AB-MECA increases contraction of isolated guinea pig trachea ex vivo when used at a concentration of 0.1 μM and increases bronchoconstriction in vivo when administered at a dose of 3 μg/kg in a guinea pig model of ovalbumin-sensitized asthma.{45428} A radiolabeled form of AB-MECA has been used for radioligand binding assays and binds to rat adenosine A1 and A3 receptors (Kds = 3.42 and 1.48 nM in COS-7 and CHO cells, respectively) and canine adenosine A2a receptors (Kd = 25.1 nM in COS-7 cells).{45429}

Size	1 mg
Shipping	dry ice
CAS Number	152918-26-8
Molecular Formula	C₁₈H₂₁N₇O₄
SMILES	[H][C@]1(O[C@H](C(NC)=O)[C@@H](O)[C@H]1O)N2C=NC3=C(NCC4=CC=C(N)C=C4)N=CN=C32
Molecular Weight	399,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2932.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.